Amyndas Pharmaceuticals Inc., of Philadelphia
C3-targeted complement inhibitor
AMY-101 had a good safety profile in healthy male volunteers administered single and multiple doses; pharmacokinetic and pharmacodynamic characteristics support subcutaneous dosing every 48 hours
Combioxin SA, of Geneva
Completed first-in-man trial, with the independent data monitoring committee supporting a positive safety profile at both dosing regimens in patients with severe CAPB due to Streptococcus pneumoniae
Immunovaccine Inc., of Halifax, Nova Scotia
Survivin-based peptide antigens
Diffuse large B-cell lymphoma
Initiated patient dosing in investigator-sponsored trial in combination with pembrolizumab (Keytruda, Merck & Co. Inc.)
Mimedx Group Inc., of Marietta, Ga.
Composite amniotic tissue membrane
Osteoarthritis of the knee
Enrolled first patient in prospective, double-blind, randomized, controlled phase IIb study
Alnylam Pharmaceuticals Inc., of Cambridge, Mass.
Hereditary ATTR amyloidosis
Patisiran demonstrated improvement of cardiomyopathy in prospectively defined subgroup of patients with cardiac amyloid involvement, relative to placebo
Brainstorm Cell Therapeutics Inc., of New York
Amyotrophic lateral sclerosis
Amended protocol so that Canada-based patients can enter
Cytori Therapeutics Inc., of San Diego
Cytori Cell Therapy
Adipose-derived regenerative cells
Stress urinary incontinence due to prostate intervention
Full enrollment was reached in the 45-patient ADRESU investigator-initiated trial in Japan
Edge Therapeutics Inc.
Aneurysmal subarachnoid hemorrhage
Discontinued on advice from data monitoring committee
Oral β3-adrenergic agonist
Started EMPOWUR trial
Wize Pharma Inc., of Hod Hasharon, Israel
Dry eye syndrome
Enrolled the first patient in a phase IV trial to treat dry eye syndrome in patients with Sjogren's syndrome vs. Systane Ultra UD eye drop
For more information about individual companies and/or products, see Cortellis.